Professor Rademacher co-founded Emergex Vaccines and has served as CEO and CSO since the Company’s formation.

He is an Emeritus Professor of Molecular Medicine at University College London and a serial entrepreneur. He co-founded Oxford GlycoSciences, the first of Oxford University’s biotech spin-outs, which, in 1998, was listed on the London Stock Exchange, reached a market capitalisation of £1.7 billion. After moving to UCL, Professor Rademacher founded several biotech spin-out companies, including Rodaris Pharmaceuticals Ltd.

In 2000, he entered into a collaboration with the Spanish Research Council and founded Midatech Ltd as a spin-out of the Consejo Superior de Investigationes Cientificas (CSIC). This expanded his portfolio of company start-ups into the field of nanomedicine, in which Professor Rademacher holds 19 patents, including being an author on the Midatech nanoparticle patents which have been licensed by Emergex. Midatech floated on the AIM and NASDAQ stock exchanges in December 2015.

Professor Rademacher has authored over 200 publications and 50 patents. In addition to being a world leader in nanomedicine, he is also an expert in foetal-maternal medicine, having produced 25 publications and filed 5 patents related to preeclampsia.

Storme Moore-Thornicroft founded Emergex Vaccines and serves as COO.

Prior to Emergex she co-founded Midatech Limited, taking the role of Vice President, Corporate Management where she was responsible for corporate and business preparation, implementation and execution of strategy and operations resulting in technology development and commercialisation.

In her early career she served at University College London (UCL Business) as IP Manager where she was responsible for the prosecution and maintenance of IP portfolios generated for UCL spin-offs.

Dr Philip is founder, board member and COO of Immunotope, Inc., a company focused on therapeutic vaccines. He is also a co-founder and President of ImmProNano, a biotech research service company.

He previously held the position of Vice President and Chief Scientific Officer of RheoGene, a joint venture between Argonex and Rohm & Haas Co. At RheoGene, he was the Principal Investigator of two Advanced Technology Program grants, totalling $4 million. He served for 6 years as director of Regional Biotech Council, a biotech industry organization covering south eastern Pennsylvania and neighbouring New Jersey and Delaware.

Dr. Philip was one of the founders of AbCRO, a clinical trials company in the US and eight eastern European countries; he served on AbCRO’s Board of Directors, until successful exit by acquisition. He also was a member of Del-aware Crossing Investor Group and its screening committee for life science investments. He is also a General Partner in the investment fund, Renaitre LP.

Dr Yixiang Dong is a chartered accountant and currently working as a Finance Controller at Sky UK.

Prior to that he has worked at P&G as a finance manager and at Imperial College as a research scientist. He is also a partner of Trend Investment, a boutique investment firm specialised in biotech.

Dr Dong was trained as a biomedical scientist.

Sir David King is an Affiliate Partner of SYSTEMIQ, the corporate and government sustainability advisory firm.

He has held a number of senior international government roles over the past 18 years. Most recently, from 2013 until 2017, David was the UK Government Foreign Secretary’s Special Representative on Climate Change, working with 165 Climate Change Attachés in UK Embassies. At the same time he was also the Chair of the Future Cities Catapult, which aims to advance urban innovation.

From 2008 until 2012 David was a member of the President’s Advisory Council, Rwanda, and Science Advisor to UBS. He also served as Founding Director of the Smith School of Enterprise and the Environment at Oxford University at this time.

From 2000 until 2007 David was the UK Government Chief Scientific Adviser, raising awareness of the need for governments to act on climate change. He was instrumental in creating the Energy Technologies Institute, a public-private partnership between global energy and engineering companies and the UK Government. He also created an in-depth Futures process which advised Government on a wide range of long-term issues, ranging from flooding to obesity.

David was born in Durban, South Africa and educated at St John’s College, Johannesburg. He attended Witwatersrand University, graduating in Chemistry and later obtaining a PhD. David has subsequently received 23 Honorary Degrees from universities around the world. He was Head of the Department of Chemistry and the Master of Downing College at the University of Cambridge, UK. He has published over 500 papers on surface science and catalysis and on science and policy.

David was elected Fellow of the Royal Society in 1991 and became a Foreign Fellow of the American Academy of Arts and Sciences in 2002. He was knighted in 2003 and was made “Officier dans l’ordre national de la Légion d’Honeur” by the President of France in 2009.

Sergio Pagani is currently Global Head of Commodities at ANZ Banking Group in Singapore and has more than 20 years of experience in international banking, finance and capital markets.

He has an extensive track record of delivering in a variety of senior positions in Zurich, London and Singapore, including at UBS Private Banking, Bankers Trust, Deutsche Bank, Dresdner Kleinwort Wasserstein, and Mitsubishi UFJ.

Sergio is also an active investor in biotech companies, and serves as a Director on the Board of RWDC Industries, a Singapore-based company with leading technology in the field of biodegradable biopolymers.